CALM: 24-month retinal thickness outcomes from a real-world registry study of patients with chronic non-infectious uveitis affecting the posterior segment treated with the 0.18 mg fluocinolone acetonide intravitreal implant

被引：0
|
作者：
Lin, Phoebe [1 ]
Suhler, Eric B. [2 ]
机构：
[1] Cleveland Clin, Dept Ophthalmol, Cleveland, OH USA
[2] Oregon Hlth & Sci Univ, Dept Ophthalmol, Casey Eye Inst, Portland, OR USA
来源：
INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE | 2024年 / 65卷 / 07期
关键词：
D O I：
暂无
中图分类号：
R77 [眼科学];
学科分类号：
100212 ;
摘要：
6454
引用
收藏
页数：2
相关论文
共 35 条
  • [21] Preventing relapse in non-infectious uveitis affecting the posterior segment of the eye - evaluating the 0.2 μg/day fluocinolone acetonide intravitreal implant (ILUVIEN(R))
    Bodaghi, Bahram
    Quan Dong Nguyen
    Jaffe, Glenn
    Khoramnia, Ramin
    Pavesio, Carlos
    JOURNAL OF OPHTHALMIC INFLAMMATION AND INFECTION, 2020, 10 (01)
  • [22] Evaluating the Safety, Efficacy and Patient Acceptability of Intravitreal Fluocinolone Acetonide (0.2mcg/Day) Implant in the Treatment of Non-Infectious Uveitis Affecting the Posterior Segment
    Steeples, Laura R.
    Pockar, Sasa
    Jones, Nicholas P.
    Leal, Ines
    CLINICAL OPHTHALMOLOGY, 2021, 15 : 1433 - 1442
  • [23] Course of Non-infectious Uveitis Affecting the Posterior Segment: Fellow-eye Data from a 3-year Study of the Fluocinolone Acetonide Intravitreal Insert
    Sharma, Sumit
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2020, 61 (07)
  • [24] Intravitreal Fluocinolone 0.19mg Implant in the Management of Chronic Non-Infectious Uveitis: 12-Month Outcomes from a Single Tertiary Centre
    Pockar, S.
    Leal, I
    Chhabra, R.
    Jones, Np
    Steeples, Lr
    OCULAR IMMUNOLOGY AND INFLAMMATION, 2023, 31 (08) : 1572 - 1578
  • [25] Safety and Efficacy of an intravitreal 0.18 mg fluocinolone acetonide insert (FAi) for the treatment of non-infectious posterior segment uveitis (NIPU) - pooled results of two phase 3 trials
    Suhler, Eric B.
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2018, 59 (09)
  • [26] The effectiveness of the ILUVIEN® (0.2 μg per day of mg fluocinolone acetonide) implant in the treatment of non-infectious posterior uveitis-12-month outcomes from UAE
    Gurbaxani, Avinash
    Kozak, Igor
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2021, 62 (08)
  • [27] Fluocinolone acetonide 0.2 μg/day intravitreal implant in non-infectious uveitis affecting the posterior segment: EU expert user panel consensus-based clinical recommendations
    Pleyer, Uwe
    Pavesio, Carlos
    Miserocchi, Elisabetta
    Heinz, Carsten
    Devonport, Helen
    Llorenc, Victor
    Burke, Tomas
    Nogueira, Vanda
    Kodjikian, Laurent
    Bodaghi, Bahram
    JOURNAL OF OPHTHALMIC INFLAMMATION AND INFECTION, 2024, 14 (01):
  • [28] 24-Month Safety Outcomes with Every-Other-Month Injections of Intravitreal Sirolimus, a Local mTOR Inhibitor, in Subjects with Active Non-Infectious Uveitis of the Posterior Segment Participating in the SAKURA Study 1
    Quan Dong Nguyen
    OPHTHALMOLOGICA, 2016, 236 : 35 - 35
  • [29] Clinical Perspectives and Considerations With Retisert® (fluocinolone acetonide intravitreal implant) 0.59 mg in the Management of Chronic Non-infectious Uveitis of the Posterior Segment: Expertise Beyound the 3-year Follow-up Clinical Trial Data
    Nguyen, Quan Gong
    Callanan, David G.
    Eliott, Dean
    Godfrey, David G.
    Goldstein, Debra A.
    Netland, Peter A.
    Srivastava, Sunil K.
    RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES, 2009, : 1 - U1
  • [30] Fluocinolone acetonide 0.2 μg/day intravitreal implant in non-infectious uveitis affecting the posterior segment: EU expert user panel consensus-based clinical recommendations ( vol 14, 22, 2024)
    Pleyer, Uwe
    Pavesio, Carlos
    Miserocchi, Elisabetta
    Heinz, Carsten
    Devonport, Helen
    Llorenc, Victor
    Burke, Tomas
    Nogueira, Vanda
    Kodjikian, Laurent
    Bodaghi, Bahram
    JOURNAL OF OPHTHALMIC INFLAMMATION AND INFECTION, 2025, 15 (01):
1234